2. Search Result
Search Result
Results for "

fear

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

2

Peptides

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15066
    CNQX
    Maximum Cited Publications
    16 Publications Verification

    FG9065

    		 iGluR Neurological Disease
    CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .
    CNQX
  • HY-15066A
    CNQX disodium
    Maximum Cited Publications
    16 Publications Verification

    FG9065 disodium

    		 iGluR Neurological Disease
    CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist . CNQX disodium blocks the expression of fear-potentiated startle in rats .
    CNQX disodium
  • HY-W011725
    N-6-Methyl-2-deoxyadenosine

    m6dA

    		 Nucleoside Antimetabolite/Analog Mitochondrial Metabolism DNA/RNA Synthesis Neurological Disease Cancer
    N-6-Methyl-2-deoxyadenosine (m6dA) is an adenine nucleoside analogue. N-6-Methyl-2-deoxyadenosine targets nuclear processes and DNA replication machineries including WER, SATB1, TFAM, Jumu, SSBP1, DNA polymerase η and phage polymerase Gp90 exo −. N-6-Methyl-2-deoxyadenosine acts as a multifunctional epigenetic regulator that modulates transcription, DNA damage response, cell cycle, transposon silencing, stress adaptation, epigenetic crosstalk, and nucleosome organization in both prokaryotes and eukaryotes. N-6-Methyl-2-deoxyadenosine regulates mitochondrial epigenetic inheritance and is required for fear extinction memory in mice. N-6-Methyl-2-deoxyadenosine exhibits dysregulated levels in cancers. N-6-Methyl-2-deoxyadenosine can be used for the research of glioblastoma, triple negative breast cancer, and conditioned fear (fear extinction impairment) .
    N-6-Methyl-2-deoxyadenosine
  • HY-110279
    Ogerin
    2 Publications Verification

    		 GPR68 Neurological Disease
    Ogerin, a chemical probe, is a selective GPR68 positive aliasing modulator (PAM) (pEC50=6.83) with a moderate antagonistic effect on A2A (Ki=220 nM). Ogerin inhibits the fear conditioning reflex in mice and also inhibits TGF-β-induced myofibroblast differentiation of fibroblasts from multiple organ systems. Ogerin can be used in the studies of fibrotic diseases and neurological disorders .
    Ogerin
  • HY-109075A
    Tasipimidine sulfate

    		Adrenergic Receptor Neurological Disease
    Tasipimidine sulfate is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine sulfate can be utilized in research related to situational anxiety and fear .
    Tasipimidine sulfate
  • HY-175188
    MT-110

    BPN-0027490

    		 Myosin Neurological Disease
    MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .
    MT-110
  • HY-P2602
    α-Casozepine

    		GABA Receptor Neurological Disease
    α-Casozepine is an orally effective anxiolytic that binds to the benzodiazepine site of the GABAA receptor in bovine samples with an IC50 of 88 μM. α-Casozepine exerts anxiolytic and anti-stress effects on cats exposed to unfamiliar environments and dogs undergoing road transport . α-Casozepine exhibits significant anxiolytic activity in rats. α-Casozepine can be used in studies related to fear, anxiety and stress .
    α-Casozepine
  • HY-145567
    Fasedienol

    PH94B

    		 Calcium Channel Neurological Disease
    Fasedienol (PH94B) is a neurochemical stimulator of the vomeronasal organ (VON). Fasedienol significantly increases Ca ++. Fasedienol modulates the olfactory amygdala circuitry of fear and anxiety to alleviate symptoms of PMS and anxiety .
    Fasedienol
  • HY-14423
    Velneperit
    1 Publications Verification

    S2367

    		 Neuropeptide Y Receptor Neurological Disease Metabolic Disease
    Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity .
    Velneperit
  • HY-112340
    CB1 antagonist 4

    		Cannabinoid Receptor Neurological Disease Metabolic Disease
    CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC50 of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC50 of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC50 of 18.5 nM .
    CB1 antagonist 4
  • HY-110190
    VU0422288

    ML396

    		 mGluR Neurological Disease
    VU0422288 (ML396) is a positive allosteric modulator of group III mGluRs. VU0422288 inhibits mGluRs with EC50s of 125 nM, 146 nM, and 108 nM for mGluR4, mGluR7, and mGluR8, respectively in calcium mobilization assays. VU0422288 reverses deficits in contextual fear memory, social recognition, and apneas in Rett syndrome (RTT) model mice .
    VU0422288
  • HY-117709
    BRD6688

    		HDAC Neurological Disease
    BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .
    BRD6688
  • HY-100406
    (S)-MCPG
    1 Publications Verification

    (+)-MCPG

    		 mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .
    (S)-MCPG
  • HY-10900
    TCS 1102
    1 Publications Verification

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    TCS 1102 is a potent, dual orexin receptor antagonist, with Ki values of 0.2 nM and 3 nM for OX2 and OX1 receptors, respectively. TCS 1102 demonstrates excellent blood-brain barrier penetrability and moderate bioavailability in rats .
    TCS 1102
  • HY-139048
    Fluoroethylnormemantine

    		iGluR Neurological Disease
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine
  • HY-P1107A
    Antisauvagine-30 TFA
    4 Publications Verification

    aSvg-30 TFA

    		 CRFR Neurological Disease
    Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF2 receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively .
    Antisauvagine-30 TFA
  • HY-131286A
    Talaglumetad hydrochloride

    LY-544344 hydrochloride

    		 mGluR Neurological Disease
    Talaglumetad (LY-544344) hydrochloride is a prodrug of mGlu2/3 receptor agonist Eglumetad (HY-18941). Talaglumetad hydrochloride exhibits anxiolytic activity and reverses fear-induced suppression of operant responding. Talaglumetad hydrochloride shows anxiolytic effects in CCK-4-induced panic and anxiety studies. Talaglumetad hydrochloride can be used in studies on the mechanisms associated with generalized anxiety disorder .
    Talaglumetad hydrochloride
  • HY-108592
    UCL 2077

    		Potassium Channel Cardiovascular Disease Neurological Disease
    UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca 2+ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K + channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .
    UCL 2077
  • HY-109075
    Tasipimidine

    		Adrenergic Receptor Neurological Disease
    Tasipimidine is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine can be utilized in research related to situational anxiety and fear .
    Tasipimidine
  • HY-139048A
    Fluoroethylnormemantine hydrochloride

    		iGluR Neurological Disease
    Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine hydrochloride
  • HY-100822A
    (S)-(-)-HA 966

    (-)-HA 966

    		 iGluR Neurological Disease
    (S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear .
    (S)-(-)-HA 966
  • HY-15066R
    CNQX (Standard)

    FG9065 (Standard)

    		 iGluR Reference Standards Neurological Disease
    CNQX (Standard) is the analytical standard of CNQX. This product is intended for research and analytical applications. CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .
    CNQX (Standard)
  • HY-P11092
    TLQP-62 (mouse,rat)

    		Endogenous Metabolite Neurological Disease
    TLQP-62 (mouse,rat) is a secreted C-terminal peptide that can be derived from protein VGF. TLQP-62 activates the BDNF-TrkB signaling pathway, inducing acute, transient phosphorylation of TrkB receptor and downstream CREB (Ser133) phosphorylation. TLQP-62 demonstrates excellent efficacy in promoting long-term fear memory formationin wild-type mice and reversing memory impairment in VGF heterozygous knock-out mice. TLQP-62 can be used for the study of memory-related neurological disorders (e.g., Alzheimer’s disease, frontotemporal dementia) .
    TLQP-62 (mouse,rat)
  • HY-117408
    VU6004256

    		mAChR Neurological Disease
    VU6004256 is a potent and selective M1 muscarinic positive allosteric modulator (PAM) with an EC50 value of 155 nM. VU6004256 has the potential for the research of schizophrenia .
    VU6004256
  • HY-186170
    R-MDMA

    		5-HT Receptor Neurological Disease
    R-MDMA, 4-methylenedioxymethamphetamine (MDMA) isomer, is a 5-HT2A/5-HT2C receptor antagonist with an IC50 of 629 and 61.4 nM. R-MDMA promotes cortical neuron growth. R-MDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDMA can be used for the researches of post-traumatic stress disorder and depression .
    R-MDMA
  • HY-186169
    R-MDDMA

    		5-HT Receptor Drug Derivative Neurological Disease
    R-MDDMA, 4-methylenedioxymethamphetamine (MDMA) analogue, is a 5-HT2A/5-HT2C receptor modulator. R-MDDMA shows antagonistic activity against 5-HT2A/5-HT2C with IC50 values of 642 and 137 nM, and also shows partial agonist activity with EC50 values of 24.5 and 14.4 nM, but does not activate 5-HT2B receptors. R-MDDMA promotes cortical neuron growth. R-MDDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDDMA can be used for the researches of post-traumatic stress disorder and depression .
    R-MDDMA
  • HY-131286
    Talaglumetad

    LY-544344

    		 mGluR Neurological Disease
    Talaglumetad (LY-544344) is a prodrug of mGlu2/3 receptor agonist Eglumetad (HY-18941). Talaglumetad exhibits anxiolytic activity and reverses fear-induced suppression of operant responding. Talaglumetad shows anxiolytic effects in CCK-4-induced panic and anxiety studies. Talaglumetad can be used in studies on the mechanisms associated with generalized anxiety disorder .
    Talaglumetad
  • HY-100406R
    (S)-MCPG (Standard)

    (+)-MCPG (Standard)

    		 mGluR Reference Standards Neurological Disease
    (S)-MCPG (Standard) is the analytical standard of (S)-MCPG (HY-100406). This product is intended for research and analytical applications. (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .
    (S)-MCPG (Standard)
  • HY-10900R
    TCS 1102 (Standard)

    		Reference Standards Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    TCS 1102 (Standard) is the analytical standard of TCS 1102 (HY-10900). This product is intended for research and analytical applications. TCS 1102 is a potent, dual orexin receptor antagonist, with Ki values of 0.2 nM and 3 nM for OX2 and OX1 receptors, respectively. TCS 1102 demonstrates excellent blood-brain barrier penetrability and moderate bioavailability in rats .
    TCS 1102 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: